A Study of OT-101 With mFOLFIRINOX in Patients With Advanced and Unresectable or Metastatic Pancreatic Cancer
Phase 2
Recruiting
- Conditions
- Pancreatic Ductal Adenocarcinoma
- Interventions
- Drug: mFOLFIRINOX
- First Posted Date
- 2023-10-12
- Last Posted Date
- 2024-08-13
- Lead Sponsor
- Oncotelic Inc.
- Target Recruit Count
- 455
- Registration Number
- NCT06079346
- Locations
- 🇺🇸
Karmanos Cancer Center, Detroit, Michigan, United States
🇺🇸Baylor College of Medicine, Houston, Texas, United States
OT-101 in Combination With Pembrolizumab in Subjects With Malignant Pleural Mesothelioma Failing to Respond to Checkpoint Inhibition
- First Posted Date
- 2022-06-21
- Last Posted Date
- 2024-03-15
- Lead Sponsor
- Oncotelic Inc.
- Target Recruit Count
- 63
- Registration Number
- NCT05425576
- Locations
- 🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States
A Study to Evaluate the Safety and Efficacy of OT-101+Artemisinin in Hospitalized COVID-19 Subjects
- First Posted Date
- 2021-03-16
- Last Posted Date
- 2021-03-16
- Lead Sponsor
- Oncotelic Inc.
- Target Recruit Count
- 18
- Registration Number
- NCT04801017
- Locations
- 🇧🇷
Praxis Pesquisa Medica S / S Ltda, Jardim, Brazil
© Copyright 2025. All Rights Reserved by MedPath